Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.
暂无分享,去创建一个
T. Conlon | B. Byrne | R. Herzog | N. Clément | M. Corti | A. Tarantal | Gensheng Wang | B. Cleaver | Kaitlyn J. Faris | Janet M. Benson | D. Fuller
[1] B. Byrne,et al. Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction , 2015, Muscle & nerve.
[2] B. Byrne,et al. Peripheral nerve and neuromuscular junction pathology in Pompe disease. , 2015, Human molecular genetics.
[3] T. Conlon,et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study , 2014, Molecular therapy. Methods & clinical development.
[4] D. Gaudet,et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. , 2014, Human gene therapy.
[5] A. Ballabio,et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. , 2014 .
[6] B. Byrne,et al. The respiratory neuromuscular system in Pompe disease , 2013, Respiratory Physiology & Neurobiology.
[7] James M. Wilson,et al. Humoral Immune Response to AAV , 2013, Front. Immunol..
[8] K. High,et al. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.
[9] Stephan Wolf,et al. A largely random AAV integration profile after LPLD gene therapy , 2013, Nature Medicine.
[10] F. Mingozzi,et al. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. , 2013, Discovery medicine.
[11] T. Conlon,et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. , 2013, Human gene therapy.
[12] William J Feuer,et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. , 2012, Archives of ophthalmology.
[13] Pratima Chowdary,et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.
[14] B. Byrne,et al. Hypoglossal Neuropathology and Respiratory Activity in Pompe Mice , 2011, Front. Physio..
[15] B. Byrne,et al. Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2D , 2010, Annals of neurology.
[16] K. Foust,et al. Over the barrier and through the blood: To CNS delivery we go , 2009, Cell cycle.
[17] K. Foust,et al. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. , 2009, Current gene therapy.
[18] B. Byrne,et al. Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins , 2009, Annals of neurology.
[19] A. J. Roman,et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. , 2009, Human gene therapy.
[20] B. Byrne,et al. Neural deficits contribute to respiratory insufficiency in Pompe disease , 2009, Proceedings of the National Academy of Sciences.
[21] A. Pestronk,et al. Clinical features of late‐onset Pompe disease: A prospective cohort study , 2008, Muscle & nerve.
[22] B. Byrne,et al. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice , 2008, Genetic vaccines and therapy.
[23] J. Mendell,et al. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D , 2008, Neurology.
[24] Eduardo Soriano,et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy , 2007, Nature Neuroscience.
[25] Sihong Song,et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. , 2006, Human gene therapy.
[26] B. Thurberg,et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease , 2006, Laboratory Investigation.
[27] J. Rasko,et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.
[28] Samuel R Ward,et al. Density and hydration of fresh and fixed human skeletal muscle. , 2005, Journal of biomechanics.
[29] Shiu-Feng Huang,et al. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. , 2004, Chang Gung medical journal.
[30] B. Bembi,et al. Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2 , 2001, Neurology.
[31] Aryeh Routtenberg,et al. GAP-43: an intrinsic determinant of neuronal development and plasticity , 1997, Trends in Neurosciences.
[32] L. Rakić,et al. GAP-43 mRNA expression in early development of human nervous system. , 1996, Brain research. Molecular brain research.
[33] Bertorini Te,et al. RESPIRATORY INSUFFICIENCY IN ADULT-TYPE ACID MALTASE DEFICIENCY , 1993 .
[34] J. Martín,et al. Pompe's disease: An inborn lysosomal disorder with storage of glycogen , 1973, Acta Neuropathologica.
[35] S. Dimauro,et al. NERVOUS SYSTEM IN POMPE'S DISEASE: ULTRASTRUCTURE AND BIOCHEMISTRY , 1971, Journal of neuropathology and experimental neurology.
[36] R. G. Berry,et al. POMPE'S DISEASE (DIFFUSE GLYCOGENOSIS) WITH NEURONAL STORAGE. , 1965, Journal of neuropathology and experimental neurology.